Zobrazeno 1 - 10
of 17
pro vyhledávání: ''
Autor:
Chinthalapally V. Rao, Naveena B. Janakiram, Rebekah L. Ritchie, Vernon E. Steele, Altaf Mohammed, Stan Lightfoot, Laura Biddick, Venkateshwar Madka, Jagan M.R. Patlolla, Misty Brewer, Michael Sadeghi
Publikováno v:
Cancer Prevention Research. 7:1198-1209
Ornithine decarboxylase (ODC) is the key rate-limiting enzyme in the polyamine synthesis pathway and it is overexpressed in a variety of cancers. We found that polyamine synthesis and modulation of ODC signaling occurs at early stages of pancreatic p
Autor:
Young Suk Park, Yoon-La Choi, Joon Oh Park, Hye Lim Jang, Seung Tae Kim, Do Hyoung Lim, Taekyu Lim, Kyung Kee Baek, Ho Yeong Lim, Won Ki Kang, Jeeyun Lee, Jun Ho Yi, Kee Taek Jang, Se Hoon Park
Publikováno v:
Molecular Cancer Therapeutics. 10:1993-1999
Although erlotinib has become an important therapeutic option in addition to gemcitabine, the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We retrospectively studied 136 pancreatic cancer patients with available
Autor:
Joseph J. Cullen, Matthew Ough, Justine M. Ritchie, Marilyn M. Hinkhouse, Douglas R. Spitz, Ling Li, Anne Lewis
Publikováno v:
Clinical Cancer Research. 10:4550-4558
Purpose: NAD(P)H:quinone oxidoreductase (NQO1) catalyzes the two-electron reduction of quinones to hydroquinones. This reaction is believed to prevent the one-electron reduction of quinones that would result in redox cycling with generation of supero
Publikováno v:
Cancer Research. 77:LB-327
Pancreatic ductal adenocarcinoma (PDAC) still remains to be one of the most highly malignant human diseases and is resistant to the majority of current therapeutic modalities. Oncogene MYC has been known to be upregulated in PDAC and plays a key role
Publikováno v:
Cancer Research. 76:665-665
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the USA with approximately 50 000 new cases and 40 000 deaths in 2015.The 5-year survival rate has remained at 5% for the past three decades and the median sur
Autor:
Benjamin Hopkins, Carmine F. Palermo, Ramon Parsons, Roshan Ara Ahmed, Kenneth P. Olive, Stephen A. Sastra
Publikováno v:
Cancer Research. 75:A90-A90
Expression of the PTEN tumor suppressor protein is frequently altered in human pancreatic tumors, and deletion of PTEN in genetically engineered mouse (GEM) models accelerates pancreatic tumorigenesis. However, efforts to target components of the PTE
Autor:
David L. Kaplan, Eun-Sin Du, David A. Putt, Aby Joiakim, Hyesook Kim, So Hee Kim, Sung-Su Park
Publikováno v:
Cancer Research. 74:3513-3513
Protein N-acetylglucosamine modification (O-GlcNAcylation) plays a critical role in cell-cycle regulation, apoptosis and signal transduction. Thr-58 of c-Myc, a mutational hot spot in lymphomas, is a site for both phosphorylation (primed by Ser-62 ph
Publikováno v:
Cancer Research. 74:2268-2268
Pancreatic cancer is the fourth leading cause of cancer death in the USA. The 5-year survival rate has only improved from 2% to 6% in the past 35 years. TNF-related apoptosis-inducing ligand (TRAIL) or agonistic antibodies bind to death receptor 4 or
Publikováno v:
Cancer Research. 74:969-969
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy, associated with a high frequency of KRAS mutations (95%) and loss of negative growth constraints, due, in part, to frequent CDKN2A (85%), TP53 (75%) and SMAD4 (55%) mutations. PDACs also
Autor:
David A. Boothman, Gaurab Chakrabarti
Publikováno v:
Cancer Research. 74:1679-1679
Patients with pancreatic cancers have one of the highest mortality rates of any cancer with 5-year survival rates of 6%. The therapeutic responses of pancreatic cancers are highly variable and there is a desperate need for agents to specifically and